Stock·NYSE·Healthcare
Boston Scientific Corp. (BSX)
- Market cap
- $64.33B
- P/E
- 17.97
- Dividend yield
- 0.00%
- Street target
- $57.00median of 31 analysts
- 52-week range
- $41.39 $105.65
The short version
Where BSX stands today, in four lines, and what CleaRank Financial AI makes of it.
BSX at a glance
Boston Scientific Corp. (BSX): Hold, 58/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($46.09 and $59.10).
- Earnings BSX beat estimates in 8 of its last 8 quarters, yet fell the next day after 4 of those beats.
- Insiders Insiders sold $91.0M and bought $10.0M over the last 18 months.
- Valuation P/E of 18.0 against 31.9 for the Healthcare sector: a discount to peers (-44%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Boston Scientific Corp. (BSX) Hold, with a model score of 58/100.
The analysts' outlook lifts the score most: 25 of 31 analysts rate it a buy and the median target is 28.4% above the price. The trend holds it back most: the price is 24.89% below its 200-day average and 3.68% below its 50-day average, and the 50-day average is 22.02% below the 200-day. The 50-day average stands at $46.09 and the 200-day at $59.10. Over the past year the price fell 54.60%.
Only on CleaRank
Figures we compute ourselves from BSX's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $44.39 is 3.7% below the 50-day simple moving average of $46.09.Price above its 200-day average ›
The price is 24.9% below the 200-day simple moving average of $59.10.50-day average above the 200-day ›
The 50-day average ($46.09) is 22.0% below the 200-day average ($59.10), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 5% of its 52-week range, between $41.39 and $105.65.
BSX share price
Pick a period: each tab shows how far BSX has moved over it, to the last close.
Today's trading
Where BSX sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/4P/E below the sector median ›
The trailing P/E of 17.97 is 43.7% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 3.06 is 9.9% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $3.7B on revenue of $21.0B, a net margin of 17.5%.Beat estimates in most recent reports ›
BSX beat the EPS estimate in 8 of its last 8 reports.
Key statistics
The headline figures for BSX.
As of October 17, 2026, BSX trades at $44.39, with a market value of $64.33B and a P/E ratio of 17.97.
What the numbers say
CleaRank Financial AI's reading of BSX's valuation, growth and risks.
Based on trailing earnings, BSX carries a P/E of 17.97, which is 43.7% below the Healthcare sector median P/E of 31.9. The peer comparison on this page labels that gap a discount to peers. On sales, the P/S of 3.06 sits 10.0% below the sector median P/S of 3.4. Its market value stands at $64.3B.
Revenue grew 7.50% over the latest year, which is 0.6 percentage points behind the 8.1% median for Healthcare. BSX turns sales into profit at a net margin of 17.50% and an operating margin of 22.90%, alongside a return on equity of 15.34%, above the sector median of 7.3%. It also reports debt-to-equity of 0.50.
BSX reported EPS of $0.86 in its most recent earnings report, dated July 29, 2026, against the $0.83 that analysts had expected. That figure cleared the estimate by 3.61%. Even so, the share price slipped 0.09% in the following session.
BSX has beaten the EPS estimate in all 8 of its recent reports; even so, 4 of those 8 beats were followed by a lower share price the next session. The consensus EPS estimate stands at $3.26 for this fiscal year and $3.38 for next, growth of 6.4% for the current year.
Daily moves in BSX average 2.03%. For as long as the price remains beneath both moving averages, the downtrend stays a risk in its own right. The stock is 57.98% below its 52-week high of $105.65. Insider sales over the last 18 months came to $91.0M, while insider purchases totalled $10.0M. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than open-market buying.
BSX against the Healthcare sector
How BSX compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: BSX trades at a notable discount to sector peers (-44%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 6, 2025, BSX has lost 57.4% against a gain of 31.6% for XLV.
Performance against XLV
BSX and the Healthcare sector fund over the same days.
Revenue and earnings
How much BSX sells, and how much of it becomes profit.
Revenue growth: Revenue grew 19.9% in FY2025 to $20.1B, from $16.7B a year earlier.
Profit margin: The net margin was 14.4% in FY2025, up from 11.0% the year before.
Profitable: BSX earned $2.9B in FY2025.
Earnings reality check
Did BSX beat what analysts expected, and how did the stock react?
Earnings record: BSX beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 4 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 29, 2026after close | $0.83 | $0.86 | +3.61% | -0.09% | +3.69% |
| Apr 22, 2026after close | $0.79 | $0.80 | +1.27% | +1.26% | -11.90% |
| Feb 4, 2026after close | $0.78 | $0.80 | +2.56% | +2.83% | -2.69% |
| Oct 22, 2025after close | $0.71 | $0.75 | +5.63% | -1.41% | -3.42% |
| Jul 23, 2025after close | $0.73 | $0.75 | +2.74% | -1.44% | -0.93% |
| Apr 23, 2025after close | $0.67 | $0.75 | +11.94% | +2.24% | +3.99% |
| Feb 5, 2025after close | $0.66 | $0.70 | +6.06% | +0.05% | +0.76% |
| Oct 23, 2024after close | $0.59 | $0.63 | +6.78% | -2.69% | -3.96% |
As of October 17, 2026, BSX has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 4 of those beats; its latest report, on July 29, 2026, came in 3.61% above the estimate and the stock moved -0.09% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 52.5, in neutral territory.RSI above 50 ›
An RSI of 52.5 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of BSX
The score, the reasoning behind it, and what could move the price next.
Boston Scientific Corp. (BSX) sits beneath both of its main moving averages. The price of $44.39 is 3.68% below the 50-day average of $46.09 and 24.89% below the 200-day average of $59.10. Within its 52-week range the stock stands at 5%, which leaves it 7.25% above the 52-week low of $41.39. The 50-day average is 22.02% below the 200-day average, meaning the shorter trend is running weaker than the longer one.
The longer record is weaker than the recent gains suggest. Over the past year the price fell 54.60%, even though it rose 1.09% over the past month and 0.82% over the past three months. The 14-day RSI sits at 52.5, which is neutral territory, and the MACD line is negative.
Earnings beat ›
The July 29, 2026 report beat the EPS estimate by 3.61%, and the share price fell 0.09% in the first session after it.
Source: Earnings report, July 29, 2026New analyst coverage ›
Barclays started coverage at Equal-Weight on October 7, 2026.
Source: Analyst action, Barclays, October 7, 2026
Analyst downgrade ›
Citigroup downgraded it to Neutral from Buy on September 17, 2026.
Source: Analyst action, Citigroup, September 17, 2026
- The two closest levels to watch are the 50-day SMA at $46.09, which sits above the price, and the 20-day EMA at $43.66, which sits below it.
- The 14-day RSI reads 52.5, in the neutral zone, with the MACD line negative; readings above 70 or below 30 mark stretched momentum.
- BSX beat estimates in 8 of the last 8 reports. Following the July 29, 2026 report, the share price fell 0.09% in the first session.
The downtrend stays in place while BSX is below both its 50-day average at $46.09 and its 200-day average at $59.10; a close back above the 50-day would be the first step of a repair. The 50-day SMA at $46.09 is the first hurdle overhead.
If the price falls, the 20-day EMA at $43.66 is the first level it would meet below the price.
Technical indicators
Momentum and trend for BSX, from its daily closes.
As of October 17, 2026, with BSX at $44.39, its 14-day RSI is 52.5 (neutral territory), its 50-day simple moving average is $46.09 and its 200-day is $59.10.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What BSX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, BSX's 1-year correlation of daily returns is +0.28 with S&P 500 (SPY), +0.22 with Nasdaq 100 (QQQ), +0.00 with Bitcoin (BTC) and +0.02 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
25 of 31 analysts rate it a buy or strong buy, 6 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $57.00 is 28.4% above the price.More buy ratings than three months ago ›
25 of 31 rate it a buy now, against 26 of 31 three months ago.
BSX Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Initiates | Equal-Weight |
| Oct 5, 2026 | Citigroup | Maintains | Neutral |
| Sep 24, 2026 | Wells Fargo | Maintains | Equal-Weight |
| Sep 21, 2026 | Oppenheimer | Maintains | Outperform |
| Sep 17, 2026 | Citigroup | Downgrade | Neutral |
| Sep 9, 2026 | BTIG | Maintains | Buy |
As of October 17, 2026, 31 Wall Street analysts cover BSX: 25 rate it a buy or strong buy, 6 a hold and 0 a sell or strong sell. Their 12-month price targets range from $44.00 to $94.00, with a median of $57.00, 28.4% above the price of $44.39.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
BSX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from BSX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much BSX tends to move, against the market and on its own.
The long record
BSX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 2.03% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 61.5%, from September 2025 to October 2026; the price is still 59.0% below that peak.Most 1-year holds ended higher ›
75% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $19,452, against $42,055 in the S&P 500 (SPY).
BSX Drawdowns & Recovery
As of October 17, 2026, BSX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -61.5% (September 2025 to October 2026); it is still 59.0% below that peak, and 75% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into BSX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: BSX trailed the S&P 500 over this period: $19,452 against $42,055.
A $10,000 investment in BSX in October 2016 would be worth about $19,452 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to BSX, and which have not.
Strongest month, January: an average of +6.82%, up in 7 of 10 years.
Weakest month, March: an average of -4.32%, up in 3 of 10 years.
This month, October: has averaged -0.63%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, BSX's strongest calendar month has been January (average +6.82%, up in 7 of 10 years) and its weakest March (average -4.32%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in BSX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BSX today could grow to about $18,844 by 2036 in the base case, with a 90th-percentile outcome near $58,705 and a 10th-percentile outcome around $6,049. Projections are statistical simulations, not guarantees.
BSX Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $57.19 for BSX by 2030 in the base case, from $44.39 today (1.3x over 4 years). The 10th-percentile path ends near $27.88. These are outcomes of a Monte Carlo simulation run on BSX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $33.02 | $47.29 | $67.74 | |
| 2028 | $30.31 | $50.39 | $83.76 | |
| 2029 | $28.81 | $53.68 | $100 | |
| 2030 | $27.88 | $57.19 | $117 | |
| 2031 | $27.28 | $60.94 | $136 |
Method: a lognormal simulation of BSX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
BSX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $10.0M on the open market and sold $91.0M.
As of October 17, 2026, BSX insiders reported 20 open-market sales worth $91.0M and 8 open-market purchases worth $10.0M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Padraig Andrew O'Connor
Officer
|
Grant | 1.2K | - |
| Aug 25, 2026 | Susan E. Morano
Director
|
Buy | 2.0K | $100.4K |
| Aug 5, 2026 | David C Habiger
Director
|
Buy | 2.1K | $99.9K |
| Aug 4, 2026 | David C Habiger
Director
|
Buy | 1.2K | $56.9K |
| Aug 3, 2026 | Michael F Mahoney
Chief Executive Officer
|
Buy | 186.2K | $9.0M |
| Jul 31, 2026 | Edward J. Ludwig
Director
|
Buy | 5.0K | $227.4K |
| Jul 1, 2026 | Jonathan R Monson
Chief Financial Officer
|
Grant | 2.1K | - |
| May 28, 2026 | Michael F Mahoney
Chief Executive Officer
|
Grant | 386.8K | - |
| May 20, 2026 | David C Habiger
Director
|
Buy | 4.5K | $251.1K |
| May 20, 2026 | Edward J. Ludwig
Director
|
Buy | 3.6K | $202.9K |
| May 20, 2026 | Cheryl Pegus
Director
|
Buy | 1.8K | $100.0K |
| May 7, 2026 | David C Habiger
Director
|
Grant | 3.8K | - |
| May 7, 2026 | Edward J. Ludwig
Director
|
Grant | 3.8K | - |
| May 7, 2026 | Jessica L M.d. Mega
Director
|
Grant | 3.8K | - |
| May 7, 2026 | Susan E. Morano
Director
|
Grant | 5.1K | - |
| May 7, 2026 | Christophe Pierre Weber
Director
|
Grant | 2.9K | - |
| May 7, 2026 | David S Wichmann
Director
|
Grant | 3.8K | - |
| May 7, 2026 | Ellen M Zane
Director
|
Grant | 3.8K | - |
| May 1, 2026 | Arthur C Butcher
Officer
|
Grant | 2.1K | - |
| May 1, 2026 | Padraig Andrew O'Connor
Officer
|
Grant | 1.8K | - |
| Mar 2, 2026 | Susan E. Morano
Director
|
Grant | 24 | - |
| Mar 2, 2026 | Christophe Pierre Weber
Director
|
Grant | 879 | - |
| Feb 27, 2026 | Emily Woodworth
Officer
|
Grant | 838 | - |
| Feb 13, 2026 | Vance R Brown
General Counsel
|
Grant | 4.8K | - |
| Feb 13, 2026 | Vance R Brown
General Counsel
|
Grant | 29.6K | - |
| Feb 13, 2026 | Arthur C Butcher
Officer
|
Grant | 8.0K | - |
| Feb 13, 2026 | Arthur C Butcher
Officer
|
Grant | 50.8K | - |
| Feb 13, 2026 | Joseph Michael Fitzgerald
Officer
|
Grant | 69.8K | - |
| Feb 13, 2026 | Joseph Michael Fitzgerald
Officer
|
Grant | 11.1K | - |
| Feb 13, 2026 | Michael F Mahoney
Chief Executive Officer
|
Grant | 264.4K | - |
| Feb 13, 2026 | Michael F Mahoney
Chief Executive Officer
|
Grant | 41.6K | - |
| Feb 13, 2026 | Jonathan R Monson
Chief Financial Officer
|
Grant | 3.8K | - |
| Feb 13, 2026 | Padraig Andrew O'Connor
Officer
|
Grant | 2.6K | - |
| Feb 13, 2026 | Miriam O'Sullivan
Officer
|
Grant | 2.7K | - |
| Feb 13, 2026 | Emily Woodworth
Officer
|
Grant | 2.7K | - |
| Feb 12, 2026 | Vance R Brown
General Counsel
|
Grant | 1.4K | - |
| Feb 12, 2026 | Arthur C Butcher
Officer
|
Grant | 2.7K | - |
| Feb 12, 2026 | Joseph Michael Fitzgerald
Officer
|
Grant | 3.5K | - |
| Feb 12, 2026 | Michael F Mahoney
Chief Executive Officer
|
Grant | 13.7K | - |
| Feb 12, 2026 | Jonathan R Monson
Chief Financial Officer
|
Grant | 1.2K | - |
| Feb 12, 2026 | Padraig Andrew O'Connor
Officer
|
Grant | 1.1K | - |
| Feb 12, 2026 | Miriam O'Sullivan
Officer
|
Grant | 961 | - |
| Feb 12, 2026 | Emily Woodworth
Officer
|
Grant | 481 | - |
| Feb 2, 2026 | Michael F Mahoney
Chief Executive Officer
|
Sell | 160.9K | $15.0M |
| Feb 2, 2026 | Michael F Mahoney
Chief Executive Officer
|
Option | 95.8K | $2.5M |
| Dec 1, 2025 | Arthur C Butcher
Officer
|
Sell | 17.3K | $1.8M |
| Dec 1, 2025 | Arthur C Butcher
Officer
|
Option | 17.3K | $429.5K |
| Nov 28, 2025 | Miriam O'Sullivan
Officer
|
Grant | 260 | - |
| Nov 14, 2025 | Joseph Michael Fitzgerald
Officer
|
Grant | 10.3K | - |
| Nov 6, 2025 | Ellen M Zane
Director
|
Sell | 12.9K | $1.3M |
| Nov 3, 2025 | Joseph Michael Fitzgerald
Officer
|
Sell | 50.0K | $5.0M |
| Nov 3, 2025 | Joseph Michael Fitzgerald
Officer
|
Option | 50.0K | $1.3M |
| Oct 30, 2025 | Michael F Mahoney
Chief Executive Officer
|
Grant | 150.0K | - |
| Oct 28, 2025 | Ellen M Zane
Director
|
Sell | 12.9K | $1.3M |
| Oct 1, 2025 | Joseph Michael Fitzgerald
Officer
|
Sell | 50.0K | $4.9M |
| Oct 1, 2025 | Joseph Michael Fitzgerald
Officer
|
Option | 50.0K | $1.3M |
| Sep 2, 2025 | Joseph Michael Fitzgerald
Officer
|
Sell | 50.0K | $5.3M |
| Sep 2, 2025 | Joseph Michael Fitzgerald
Officer
|
Option | 50.0K | $1.3M |
| Aug 1, 2025 | Joseph Michael Fitzgerald
Officer
|
Sell | 50.0K | $5.2M |
| Aug 1, 2025 | Arthur C Butcher
Officer
|
Sell | 17.3K | $1.8M |
| Aug 1, 2025 | Arthur C Butcher
Officer
|
Option | 17.3K | $429.5K |
| Aug 1, 2025 | Joseph Michael Fitzgerald
Officer
|
Option | 50.0K | $1.3M |
| Aug 1, 2025 | Edward J. Ludwig
Director
|
Grant | 500 | - |
| Aug 1, 2025 | Jonathan R Monson
Chief Financial Officer
|
Grant | 1.1K | - |
| Jul 29, 2025 | Yoshiaki Fujimori
Director
|
Sell | 2.9K | $310.4K |
| Jul 25, 2025 | Edward J. Ludwig
Director
|
Sell | 4.0K | $424.1K |
| Jul 1, 2025 | Joseph Michael Fitzgerald
Officer
|
Sell | 50.0K | $5.3M |
| Jul 1, 2025 | Vance R Brown
General Counsel
|
Grant | 4.0K | - |
| Jul 1, 2025 | Joseph Michael Fitzgerald
Officer
|
Option | 50.0K | $1.3M |
| Jun 4, 2025 | Joseph Michael Fitzgerald
President
|
Sell | 56.4K | $5.8M |
| Jun 4, 2025 | Joseph Michael Fitzgerald
President
|
Option | 56.4K | $1.5M |
| Jun 2, 2025 | Michael F Mahoney
Chief Executive Officer
|
Sell | 164.4K | $17.1M |
| Jun 2, 2025 | Michael F Mahoney
Chief Executive Officer
|
Option | 105.6K | $2.2M |
| May 29, 2025 | Edward J. Ludwig
Director
|
Sell | 4.0K | $418.4K |
| May 21, 2025 | Vance R Brown
General Counsel
|
Sell | 4.8K | $513.6K |
| May 8, 2025 | Yoshiaki Fujimori
Director
|
Grant | 2.1K | - |
| May 8, 2025 | David C Habiger
Director
|
Grant | 2.1K | - |
| May 8, 2025 | Edward J. Ludwig
Director
|
Grant | 2.1K | - |
| May 8, 2025 | Jessica L M.d. Mega
Director
|
Grant | 2.1K | - |
| May 8, 2025 | Susan E. Morano
Director
|
Grant | 2.7K | - |
| May 8, 2025 | John E Sununu
Director
|
Grant | 2.1K | - |
| May 8, 2025 | David S Wichmann
Director
|
Grant | 2.1K | - |
| May 8, 2025 | Ellen M Zane
Director
|
Grant | 2.1K | - |
| May 5, 2025 | John Bradley Sorenson
Officer
|
Sell | 4.6K | $478.0K |
| May 2, 2025 | Arthur C Butcher
Officer
|
Grant | 2.1K | - |
| May 2, 2025 | John Bradley Sorenson
Officer
|
Grant | 4.2K | - |
| May 1, 2025 | Michael F Mahoney
Chief Executive Officer
|
Sell | 164.4K | $16.9M |
| May 1, 2025 | Arthur C Butcher
Officer
|
Sell | 17.3K | $1.8M |
| May 1, 2025 | Arthur C Butcher
Officer
|
Option | 17.3K | $429.5K |
| May 1, 2025 | Michael F Mahoney
Chief Executive Officer
|
Option | 105.6K | $2.2M |
| Apr 21, 2025 | Vance R Brown
General Counsel
|
Sell | 4.8K | $458.9K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.